Once-daily glycopyrronium via the Breezhaler® device for the treatment of COPD: pharmacological and clinical profile.

Expert review of clinical pharmacology

Volumn 6, Issue 5, 2013, Pages 503-517

  Molimard, Mathieu ^a   D'Andrea, Peter ^b  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPYRRONIUM BROMIDE; MUSCARINIC RECEPTOR BLOCKING AGENT;

ANIMAL; CHEMICAL STRUCTURE; CLINICAL TRIAL (TOPIC); DRUG ADMINISTRATION; DRY POWDER INHALER; HUMAN; INHALATIONAL DRUG ADMINISTRATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; DRY POWDER INHALERS; GLYCOPYRROLATE; HUMANS; MOLECULAR STRUCTURE; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 84891401365     PISSN: None     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2013.828419     Document Type: Review

References (0)